Non-Hodgkin Lymphoma

Zevalin, a radioimmunotherapeutic, shows high response, durable remissions

Published in Cancer Weekly, June 24th, 2003

The final report from a clinical trial of the radioimmunotherapy Yttrium-90 ibritumomab tiuxetan (Zevalin) presented at the 39th annual meeting of the American Society of Clinical Oncology (ASCO) concluded that Zevalin produces high response rates and durable remissions when used as a treatment for low-grade, follicular, and transformed non-Hodgkin's Lymphoma (NHL).

Responses extending beyond the 4-year-mark are described with the average duration in 34% of the patients that had a complete response to Zevalin (vs. 16% in the control group) currently approaching 2 years. The updated trial results are based on a pivotal clinical trial that included 143 patients randomized...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-06-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry